Dihydrotestosterone is an androgen hormone derived from testosterone. The conversion happens via an enzyme called 5-alpha reductase (5-AR), which exists in two functionally distinct isoforms: type I, found primarily in sebaceous glands and the liver, and type II, particularly important within hair follicles and the prostate gland. Type II is the predominant isoform implicated in follicle miniaturisation, though both isoforms are present in scalp tissue in different distributions.

This distinction matters: the local conversion of testosterone to DHT within the follicle itself, catalysed largely by type II 5-AR in dermal papilla cells, is what drives androgen-mediated miniaturisation. Circulating DHT levels in the bloodstream tell an incomplete story: what is happening inside the dermal papilla is largely a local metabolic event.

DHT binds to androgen receptors with higher affinity than testosterone itself, and with a substantially slower dissociation rate once bound. This makes DHT a more potent activator of androgen receptor signalling than testosterone, despite being present at lower absolute concentrations in circulation.

The dermal papilla is the connective tissue core at the base of each follicle. It governs the behaviour of surrounding keratinocytes and directly regulates the hair growth cycle: how long anagen lasts, how deep the follicle anchors, how thick the hair shaft grows. Dermal papilla cells express androgen receptors, and in follicles with genetic sensitivity to DHT, these receptors are expressed at higher levels than in non-balding follicles.

When DHT binds to androgen receptors in the papilla, the resulting DHT-receptor complex translocates into the cell nucleus and alters gene expression. The downstream effects include upregulation of factors that curtail anagen and downregulation of those that promote growth. The result, played out over successive hair cycles, is progressive follicular miniaturisation: anagen shortens with each cycle, the follicle produces a finer, shorter, less pigmented shaft, and eventually transitions to producing vellus hair.

One of the most telling features of androgenetic alopecia is its regional specificity. The follicles of the vertex and temporal scalp are susceptible; the occipital follicles (the back and sides) are largely resistant, even in advanced cases. This distinction is not hormonal. A man with advanced AGA has the same circulating DHT reaching his occipital follicles as his vertex follicles. The difference is intrinsic to the follicles themselves.

Research examining dermal papilla cells extracted from balding versus non-balding regions of the same individual shows higher androgen receptor expression in cells from susceptible areas. The follicles in the temporal and vertex regions are, at the cellular level, more responsive to androgen signalling. This sensitivity is largely genetically determined, and the androgen receptor gene, located on the X chromosome, has been implicated in susceptibility, though the genetics of AGA are polygenic and not straightforwardly maternal-line in their inheritance.

This also explains why absolute DHT levels are a poor predictor of hair loss. Some individuals with elevated circulating DHT experience minimal thinning; others with entirely normal androgen levels develop significant AGA. The inherited sensitivity of individual follicles to DHT is one of the major determinants of how the condition progresses, alongside local 5-AR expression, receptor sensitivity, and downstream signalling factors.

DHT's effect on papilla gene expression is not the only process at play in AGA. Androgen signalling in susceptible follicles is also associated with progressive perifollicular fibrosis and changes in the local vascular environment. Research by Yoo et al. (2006) demonstrated that testosterone treatment increases type I procollagen expression in scalp dermal fibroblasts via TGF-beta signalling, providing a mechanism for the connective tissue accumulation around susceptible follicles that is commonly seen in AGA histology.

The relationship between AGA and vascular changes is an area of active investigation. Altered blood supply and perifollicular structural changes represent a second dimension of the condition that sits downstream of androgen signalling and is covered in more detail in the article on androgenetic alopecia and the vascular hypothesis. Understanding this layer matters because it points to mechanistic targets that differ from the androgen pathway, where compounds supporting tissue remodelling and vascularisation may have a complementary role.

If DHT acting on androgen-sensitive follicles is the central mechanism, the most direct intervention is reducing the availability of DHT at those follicles. This is the mechanism behind 5-alpha reductase inhibitors, the best-evidenced pharmacological approach to AGA.

Finasteride and dutasteride are prescription-only in the UK, classified as medicines acting on a hormonal pathway. Both have extensive evidence for slowing and in some cases partially reversing miniaturisation in men with AGA. They require consistent, long-term use: discontinuation typically leads to resumed progression within twelve months as DHT levels return to baseline.

For women, the picture is more complex. Many with female pattern hair loss (FPHL) do not have elevated androgens, and the role of peripheral DHT sensitivity versus other hormonal signals is less clearly delineated. Anti-androgen approaches including spironolactone are used off-label in women with hormone-related hair loss, but the evidence base is considerably thinner than for male AGA with 5-AR inhibitors.

Addressing DHT at the level of enzyme inhibition is the most upstream intervention available for AGA. But the androgen pathway does not operate in isolation. The miniaturisation process involves changes to the follicular microenvironment: changes in local vascularity, progressive fibrosis, and a shift in the signalling environment of the dermal papilla that affects keratinocyte behaviour. These changes may persist to varying degrees even when DHT levels are substantially reduced, and they represent additional targets for supportive intervention.

Topical copper peptides have been studied in the context of these downstream effects. GHK-Cu (Copper Tripeptide-1) has a research profile centred on tissue remodelling, extracellular matrix support, and upregulation of growth factors including VEGF. AHK-Cu (Copper Tripeptide-3), a synthetic analogue explored specifically in hair-related research, was shown in a cell culture and organ culture study by Pyo et al. (2007) to promote hair follicle elongation and dermal papilla cell proliferation in vitro. Neither compound acts on the androgen pathway directly, and neither replaces interventions that address DHT itself.

DHT suppression addresses the cause while topical actives are oriented toward the follicular environment: the conditions under which follicles operate. A protocol that considers both layers is more comprehensive than one targeting only androgen signalling. The hair loss protocol framework covers how these approaches can be combined in practice.

This article is provided for educational purposes. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. For prescription treatments including finasteride or dutasteride, consult a qualified healthcare professional.

AmpleLab.